InMed Pharmaceuticals Inc.
INM
$1.34
$0.021.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.27% | 7.50% | -12.53% | -11.94% | 5.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.27% | 7.50% | -12.53% | -11.94% | 5.17% |
| Cost of Revenue | -6.07% | -7.46% | -2.79% | -7.60% | 20.92% |
| Gross Profit | 2.75% | 55.02% | -27.63% | -18.89% | -17.87% |
| SG&A Expenses | 11.27% | 14.33% | 12.68% | 12.71% | 7.28% |
| Depreciation & Amortization | -3.60% | -3.05% | -1.56% | 1.49% | 5.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.10% | 1.01% | 6.02% | 0.93% | -0.13% |
| Operating Income | -9.13% | 2.66% | -21.73% | -11.02% | 3.45% |
| Income Before Tax | -20.58% | -6.44% | -36.71% | -24.55% | 2.27% |
| Income Tax Expenses | -- | -- | 294.44% | 115.15% | 12.70% |
| Earnings from Continuing Operations | -20.46% | -6.34% | -36.79% | -24.60% | 2.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.46% | -6.34% | -36.79% | -24.60% | 2.26% |
| EBIT | -9.13% | 2.66% | -21.73% | -11.02% | 3.45% |
| EBITDA | -9.53% | 2.65% | -22.52% | -11.33% | 3.71% |
| EPS Basic | 48.60% | 64.31% | 49.85% | 57.65% | 70.48% |
| Normalized Basic EPS | 48.54% | 64.29% | 49.89% | 57.67% | 70.49% |
| EPS Diluted | 48.60% | 64.31% | 49.85% | 57.65% | 70.48% |
| Normalized Diluted EPS | 48.54% | 64.29% | 49.89% | 57.67% | 70.49% |
| Average Basic Shares Outstanding | 266.25% | 156.61% | 139.48% | 154.74% | 222.31% |
| Average Diluted Shares Outstanding | 266.25% | 156.61% | 139.48% | 154.74% | 222.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |